New Therapeutic Agents in Thrombosis and Thrombolysis, Second Edition, (Fundamental and Clinical Cardiology, V. 46)

Presents new chapters discussing the latest research on low-molecular-weight heparins, as well as agents such as pentasaccharide, TFP1, soluble thrombomodulin, and alfimeprase. Completely revised and expanded throughout, New Therapeutic Agents in Thrombosis and Thrombolysis details strategies to ·target conventional and recently characterized pathways of hemostasis ·minimize the prothrombotic function of activated platelets ·assess the biochemical and pharmacological effects of antithrombotic agents and discusses ·the use of animal models for determination of antithrombotic drug efficacy ·antithrombotic therapy as a key component of cardiovascular disease management ·the management of thromboembolic events in children and pregnant women Supplemented with more than 2000 contemporary references, New Therapeutic Agents in Thrombosis and Thrombolysis is an authoritative source for cardiologists, internists, primary care physicians, vascular medicine specialists, cardiovascular and vascular surgeons, hematologists, pulmonologists, critical care physicians, pharmacologists, pharmaceutical researchers, and fellows, residents, and graduate and medical school students in these disciplines.